Trichilemmoma

Back

Background

In 1962, Headington and French first described trichilemmoma as a benign neoplasm with differentiation toward pilosebaceous follicular epithelium,[1] or outer root sheath. Although unusual, at times, a central zone of desmoplasia may develop and thus be termed desmoplasia trichilemmoma.[2] While benign in nature, the significance of trichilemmoma resides in the association with Cowden disease (ie, multiple hamartoma syndrome), nevus sebaceous, and the need to differentiate trichilemmomas from other more aggressive cutaneous tumors, such as trichilemmal carcinoma.

Clinically, trichilemmomas present as well-defined, smooth, asymptomatic papules or verrucoid growths. They may appear as a solitary or multiple lesions, and they usually are found on the head and face (see the image below). These papules often mimic a basal cell carcinoma or a verruca.



View Image

A patient with trichilemmoma papules on the face.

Trichilemmomas are often reported in association with several other neoplasms. Trichilemmoma is most commonly found secondary to nevus sebaceous of Jadassohn.[3] . Nevus sebaceous is classified as a congenital cutaneous hamartoma that presents on the scalp or face sometime between birth and childhood development.[2] Several articles have reported trichilemmomas also appearing alongside trichoblastoma, sebaceous adenoma, and syringocystadenoma papilliferum.[4, 5]

When multiple trichilemmomas are present, Cowden disease should be suspected, especially if associated with oral fibromas, goiter, gastrointestinal polyposis, thyroid disease, or a family history of breast cancer.

Pathophysiology

The underlying cause of trichilemmomas is unknown. Because of its histologic similarity to a wart, some researchers have investigated a viral etiology.[6, 7]

Johnson et al[8] performed histologic and ultrastructural analyses of 10 hyperkeratotic lesions on the extremities and 2 keratotic lesions on the face in a patient with Cowden disease. They were unable to find evidence of a viral infection in the tissues examined. Leonardi et al[9] performed a study on 25 trichilemmomas, revealing no evidence of human papillomavirus DNA in the lesions. Most trichilemmomas, therefore, appear to represent a benign tumor with differentiation towards the follicular outer root sheath (trichilemma).[7]

Stierman et al[10] were unable to detect human papillomavirus (HPV)–1, HPV-2, or mixed genital-type HPV infection in trichilemmomas using in situ hybridization. It was suggested that the association between HPV infection and the hair follicle is both one of the permanent sources of HPV DNA and the site of origin for trichilemmomas.[11] The development of trichilemmomas may be independent factors associated with increasing age, rather than HPV being an oncogenic stimulus for trichilemmomas.

Conversely, Rohwedder et al used the polymerase chain reaction (PCR) technique to show 11 cases of HPV-positive trichilemmoma. So far, HPV types 6b, 15, 17, 23, 27, and 28 have been identified in both solitary trichilemmoma lesions and in patients with Cowden syndrome.[11, 12]

Cowden syndrome is a rare autosomal dominant condition characterized by the formation of multiple types of hamartomas and neoplastic growths, which may be found throughout different body systems. This syndrome is thought to be due to the PTEN mutation, a germline mutation in exon 8 of the phosphatase and tensin homolog deleted on chromosome 10.[13] It is a point mutation of C to T at codon 1003 (CGA → TGA, arginine → stop codon). This defect demonstrates incomplete genetic penetrance with variable expressivity. Loss of heterozygosity may lead to tumor formation.[14]

The syndrome is allelic to other PTEN -related syndromes such as Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma) and Bannayan-Riley-Ruvalcaba syndrome, which is characterized by genital lentigines and hamartomatous growths. Families or patients with overlapping features have been described.[15, 16]

Etiology

The cause of a trichilemmoma is unknown. Because trichilemmoma shares some morphologic and histologic features with a verruca, some researchers have postulated that a virus may induce these lesions. Increased risk has also been found when subjects have a history of long exposure to sunlight.[17]

Epidemiology

Frequency

United States

Trichilemmomas are relatively common benign neoplasms of the follicular epithelium. Their true incidence is hard to determine and is probably underestimated. Approximately 40 cases per 100,000 consecutive skin biopsies may be found every year in any given dermatopathologic laboratory. Unlike isolated trichilemmomas, multiple trichilemmomas associated with Cowden disease are very rare.

International

The international frequency is unknown.

Race

Trichilemmomas may occur in any race. They are most common in white females, but they have also been reported in Chinese, Japanese, and black patients.

Sex

The male-to-female ratio of trichilemmomas is 1:1; however, Cowden disease has a female predominance, with a male-to-female ratio of 1:3.

Age

Trichilemmomas predominantly occur in adult patients aged 20-80 years. However, onset may occur as early as age 4 years, with a median age of onset at 30 years.[14]

Desmoplastic trichilemmomas (a histologic subtype of trichilemmoma) predominantly occur in white men over a wide age range, and the highest frequency is in the fifth decade.

One rare case of a trichilemmoma following a blaschkoid pattern has been noted in a 13-year-old boy. It is the first case seen as such.[18]

Prognosis

Trichilemmomas are benign follicular epithelial neoplasms. Of themselves, trichilemmomas are associated with minimal morbidity and no mortality. These tumors usually need to be differentiated clinically from a verruca or a basal cell carcinoma. The only morbidity associated with these tumors occurs if they are treated as a basal cell carcinoma before histologic confirmation is obtained.

Patient Education

Educate each patient with a trichilemmoma regarding the benign nature of this epithelial neoplasm. Further education regarding its association with Cowden disease may also be provided, particularly if other clinical evidence for Cowden disease exists. Patients should be informed that they are at higher risk for the development of trichilemmoma the more they are subjected to sun exposure. In addition, if nevus sebaceous remains untreated, it has a 10-20% chance of transforming into a malignant form. Appropriate plans and treatment should always be instituted.[17]

History

Patients with trichilemmomas usually give a history of a slow-growing, asymptomatic papule and/or plaque on the face. Such lesions may be solitary or multiple. Patients often desire reassurance that they do not have a skin cancer and/or seek an evaluation for cosmetic removal of the lesions.

If presenting in a nevus sebaceous of Jadassohn, a trichilemmoma may appear as a new growth within the lesion. No single feature allows the clinical diagnosis of a trichilemmoma, but rather this diagnosis is usually rendered histologically. However, if multiple lesions are present on the face, trichilemmomas associated with Cowden syndrome may be suspected. Once the diagnosis of trichilemmoma has been given, reevaluating the patient for clinical features of Cowden syndrome may be prudent.

Physical Examination

Patients with trichilemmomas usually present with either a single papule or multiple, small, flesh-colored papules that are 1-5 mm in diameter on the face or the neck. When these lesions grow in size, small plaques may be found, particularly in the nasolabial fold region. As trichilemmomas slowly enlarge, they often produce a hyperkeratotic surface suggestive of a verruca or a cutaneous horn. Besides the central part of the face, the ears, the forearms, the hands, or within a nevus sebaceous of Jadassohn are other typical sites that are examined for these cutaneous lesions.

Trichilemmoma commonly stems from nevus sebaceous, which usually is found on the face and scalp. However, cases have also been noted on the eyelid and anus.[19, 20]

If a diagnosis of trichilemmoma is rendered, the patient should be completely examined for evidence of Cowden syndrome. (See images below.) Ten key physical features to look for in establishing the diagnosis of Cowden syndrome include the following:

In 1983, Salem and Steck[21] proposed diagnostic criteria for Cowden syndrome. See Cowden Disease (Multiple Hamartoma Syndrome) for a more definitive discussion in this area.



View Image

Clinical image of the face of a patient with Cowden syndrome.



View Image

Clinical image of the oral mucosa of a patient with Cowden syndrome.



View Image

Clinical image of palmar keratoses in a patient with Cowden syndrome.



View Image

Clinical image of sclerotic fibroma in a patient with Cowden syndrome.



View Image

Clinical image of multiple trichilemmomas in a patient with Cowden syndrome.

Patients with desmoplastic trichilemmomas usually present with lesions less than 1 cm in diameter found predominantly on the face, the neck, the scalp, and, sometimes, on the chest or the vulva. Several reports have described desmoplastic trichilemmomas occurring on the upper eyelid.[22, 23] They may be indurated, with a depressed central region and a raised, annular border. Desmoplastic trichilemmomas, although not associated with Cowden disease, have been described arising from a nevus sebaceous.[3, 24]

Laboratory Studies

If clinical evidence of Cowden syndrome is present, the following tests may be considered in establishing the diagnosis and in searching for potential malignancies:

Imaging Studies

No imaging studies are needed for the evaluation of a trichilemmoma. However, the following imaging studies may be of use when completing a workup for Cowden syndrome:

Procedures

A skin biopsy is used to establish the diagnosis of a trichilemmoma. A shave biopsy is most commonly performed (see Histologic Findings). Some practices have used several variant types of antibiotics in attempts to decrease the size of the trichilemmoma.[25]

Histologic Findings

The following are histologic features found in a trichilemmoma (see the images below); these features assist in establishing the diagnosis:

The histologic differential diagnosis includes a hidroacanthoma simplex, which usually demonstrates ductal differentiation. A clear basal cell carcinoma should also be considered but can be excluded based on the presence of mucinous stroma, mitoses, and peripheral palisading with an absence of an eosinophilic hyaline cuticle. In tumor tissue in mice, nestin immunoreactivity was observed in immunoreactivity but not in basal cell carcinoma.[26]

Other epithelial neoplasms, such as the tumor of the follicular infundibulum (see the image below), may be considered in the differential diagnosis. Trichilemmal carcinoma may be considered, but excluded, based on its invasive growth pattern and many mitoses. An immunohistochemical study of cytokeratins suggests that an absence of cytokeratins 15 and 16 in trichilemmal carcinoma may be related to transformation from trichilemmoma to its trichilemmal carcinoma.[27]



View Image

Tumor of the follicular infundibulum.

Several reports have stated that the use of CD34 immunostaining in tumors completely or partially differentiated toward the external root sheath of the hair follicle, such as trichilemmoma.[28]

Desmoplastic trichilemmoma demonstrates a biphasic growth pattern, having features of a lobulated tumor and cells that form narrow, irregular cords, which penetrate into the dermis. The stroma surrounding the tumor cords appears sclerotic. An inflammatory cell infiltrate is often seen surrounding the epithelial strands of the tumor. Because of these features, differentiating this tumor from an invasive squamous cell carcinoma or a sclerosing basal cell carcinoma is important.[29] CD34 expression has been particularly useful in the differentiation of desmoplastic trichilemmoma from other cutaneous tumors with dense collagenous stroma.[30]



View Image

Low-power histologic view of a desmoplastic trichilemmoma.



View Image

High-power histologic view of a desmoplastic trichilemmoma.

Approach Considerations

The best medical treatment of a tricholemmoma is to begin by establishing the correct diagnosis. Because these tumors are benign, no medical treatment is required. However, a few treatment options are available, ranging from simple surgical excision to carbon dioxide laser tissue ablation. Even though most tumors are benign, they always should be continually monitored, as malignant transformation has occurred.[17] Trichilemmoma may commonly vary in size, and it should be reevaluated should continual growth occur.[25]

Surgical Care

A standard surgical approach to a patient with a trichilemmoma is to perform a shave biopsy. This procedure provides a tissue specimen for histologic examination and facilitates removal of the epithelial growth. If the shave biopsy is performed flush to the skin surface, it often produces an excellent cosmetic result. However, performing a shave biopsy does not eliminate the possibility of a recurrence.

Excision is an option but is less commonly performed because of the benign nature of this neoplasm and its common location on the face.

Electrodesiccation may be used to remove a trichilemmoma. However, electrodesiccation followed by curettage is not indicated for this benign neoplasm. This procedure produces unnecessary and unsightly scarring.

One report describes successful treatment of desmoplastic trichilemmoma (a variant of trichilemmoma) with Mohs micrographic surgery.[31]

Probably the most elegant procedure to date for removing a trichilemmoma is the use of a carbon dioxide laser for tissue ablation. Carbon dioxide laser has been used for removal of a wide range of epidermal and dermal growths or neoplasms. Under local anesthesia, the hypertrophic and hyperkeratotic epithelium characteristic of a trichilemmoma may be rapidly and precisely vaporized.

The coagulated tissue subsequently may be wiped away. This process is repeated until the tissue is flush with the surrounding skin surface and/or the tumor has been destroyed. The remaining tissue and thermal debris is allowed to heal and usually separates from the epidermis in 3-5 days after the procedure. Reepithelialization is usually complete within 4 weeks.

This procedure is particularly useful if multiple trichilemmomas are present (eg, Cowden syndrome).

The carbon dioxide laser has the following advantages: It allows for precise tissue ablation. Multiple lesions can be treated with ease. The procedure can be performed quickly. Morbidity is minimal. Patient recovery time is relatively short. Cosmetic results are usually excellent.

Consultations

If the diagnosis of trichilemmoma is established and no other clinical features or family history of Cowden syndrome is found, then no further consultation is needed. However, if the medical provider finds evidence of Cowden syndrome, referral to a dermatologist is needed. Secondary referrals to a gastroenterologist, internist, endocrinologist, and a surgeon may be needed.

Author

William P Baugh, MD, Assistant Clinical Professor of Dermatology, Western University of Health Sciences; Medical Director, Full Spectrum Dermatology; Consulting Staff, Department of Dermatology, St Jude Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Cynthia L Chen, DO, DO, Intern, Pacific Hospital of Long Beach, California

Disclosure: Nothing to disclose.

David Barnette, Jr, MD, Voluntary Associate Clinical Professor, University of California San Diego School of Medicine

Disclosure: Nothing to disclose.

James H Kerr, MD, Former Head (Retired), Department of Dermatology, Naval Medical Center at San Diego

Disclosure: Nothing to disclose.

Natalie Ana Baugh, California State University, Long Beach

Disclosure: Nothing to disclose.

Walter D Kucaba, DO, Private Family Practice, Simpsonville, South Carolina

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

David P Fivenson, MD, Associate Director, St Joseph Mercy Hospital Dermatology Program, Ann Arbor, Michigan

Disclosure: Nothing to disclose.

References

  1. Headington JT, French AJ. Primary neoplasms of the hair follicle. Histogenesis and classification. Arch Dermatol. 1962 Oct. 86:430-41. [View Abstract]
  2. Jardim MML, Souza BCE, Fraga RC, Fraga RC. Rare desmoplastic trichilemmoma associated with sebaceous nevus. An Bras Dermatol. 2017 Nov-Dec. 92 (6):836-837. [View Abstract]
  3. Baykal C, Buyukbabani N, Yazganoglu KD, Saglik E. [Tumors associated with nevus sebaceous]. J Dtsch Dermatol Ges. 2006 Jan. 4(1):28-31. [View Abstract]
  4. Manonukul J, Omeapinyan P, Vongjirad A. Mucoepidermoid (adenosquamous) carcinoma, trichoblastoma, trichilemmoma, sebaceous adenoma, tumor of follicular infundibulum and syringocystadenoma papilliferum arising within 2 persistent lesions of nevus sebaceous: report of a case. Am J Dermatopathol. 2009 Oct. 31(7):658-63. [View Abstract]
  5. Wang Y, Bu WB, Chen H, Zhang ML, Zeng XS, Zhao L. Basal cell carcinoma, syringocystadenoma papilliferum, trichilemmoma, and sebaceoma arising within a nevus sebaceus associated with pigmented nevi. Dermatol Surg. 2011 Dec. 37(12):1806-10. [View Abstract]
  6. Ackerman AB. Trichilemmoma. Arch Dermatol. 1978 Feb. 114(2):286. [View Abstract]
  7. Stierman S, Chen S, Nuovo G, Thomas J. Detection of human papillomavirus infection in trichilemmomas and verrucae using in situ hybridization. J Cutan Pathol. 2010 Jan. 37(1):75-80. [View Abstract]
  8. Johnson BL, Kramer EM, Lavker RM. The keratotic tumors of Cowden's disease: an electronmicroscopic study. J Cutan Pathol. 1987 Oct. 14(5):291-8. [View Abstract]
  9. Leonardi CL, Zhu WY, Kinsey WH, Penneys NS. Trichilemmomas are not associated with human papillomavirus DNA. J Cutan Pathol. 1991 Jun. 18(3):193-7. [View Abstract]
  10. Stierman S, Chen S, Nuovo G, Thomas J. Detection of human papillomavirus infection in trichilemmomas and verrucae using in situ hybridization. J Cutan Pathol. 2010 Jan. 37(1):75-80. [View Abstract]
  11. Schaller J, Rohwedder A, Burgdorf WH, Itin PH, Lautenschlager S. Identification of human papillomavirus DNA in cutaneous lesions of Cowden syndrome. Dermatology. 2003. 207(2):134-40. [View Abstract]
  12. Rohwedder A, Keminer O, Hendricks C, Schaller J. Detection of HPV DNA in trichilemmomas by polymerase chain reaction. J Med Virol. 1997 Feb. 51(2):119-25. [View Abstract]
  13. Harada N, Sugimura T, Yoshimura R, et al. Novel germline mutation of the PTEN gene in a Japanese family with Cowden disease. J Gastroenterol. 2003. 38(1):87-91. [View Abstract]
  14. Umemura K, Takagi S, Ishigaki Y, Iwabuchi M, Kuroki S, Kinouchi Y. Gastrointestinal polyposis with esophageal polyposis is useful for early diagnosis of Cowden's disease. World J Gastroenterol. 2008 Oct 7. 14(37):5755-9. [View Abstract]
  15. Pezzolesi MG, Li Y, Zhou XP, Pilarski R, Shen L, Eng C. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes. Am J Hum Genet. 2006 Nov. 79(5):923-34. [View Abstract]
  16. Sarquis MS, Agrawal S, Shen L, Pilarski R, Zhou XP, Eng C. Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Hum Genet. 2006 Jul. 79(1):23-30. [View Abstract]
  17. Lee CA, Kang SJ, Jeon SP, Sun H, Kang MS. Simultaneous Development of Three Different Neoplasms of Trichilemmoma, Desmoplastic Trichilemmoma and Basal Cell Carcinoma Arising from Nevus Sebaceus. Arch Craniofac Surg. 2017 Mar. 18 (1):46-49. [View Abstract]
  18. Jha AK, Prasad S, Sinha R. Linear trichilemmoma following a blaschkoid pattern: a clinical dilemma. J Eur Acad Dermatol Venereol. 2016 Feb. 30 (2):299-301. [View Abstract]
  19. Lee K, Chi M. A case of eyelid desmoplastic trichilemmoma. J Korean Ophthal Soc. 16 Apr 2018. 59(4):376-78.
  20. Cui A, Mei Z, Cui L. Anal malignant proliferative trichilemmoma: report of a rare case with review of literature. Int J Clin Exp Pathol. 2015. 8 (3):3349-53. [View Abstract]
  21. Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol. 1983 May. 8(5):686-96. [View Abstract]
  22. Boulton JE, Sullivan TJ, Whitehead KJ. The eyelid is a site of occurrence of desmoplastic trichilemmoma. Eye. 2001 Apr. 15(Pt 2):257. [View Abstract]
  23. Keskinbora KH, Buyukbabani N, Terzi N. Desmoplastic trichilemmoma: a rare tumor of the eyelid. Eur J Ophthalmol. 2004 Nov-Dec. 14(6):562-4. [View Abstract]
  24. Roson E, Gomez Centeno P, Sanchez-Aguilar D, Peteiro C, Toribio J. Desmoplastic trichilemmoma arising within a nevus sebaceus. Am J Dermatopathol. 1998 Oct. 20(5):495-7. [View Abstract]
  25. Ng DW. Trichilemmoma in Childhood. J Pediatr Health Care. 2016 Sep-Oct. 30 (5):491-4. [View Abstract]
  26. Kanoh M, Amoh Y, Sato Y, Katsuoka K. Expression of the hair stem cell-specific marker nestin in epidermal and follicular tumors. Eur J Dermatol. 2008 Sep-Oct. 18(5):518-23. [View Abstract]
  27. Kurokawa I, Senba Y, Nishimura K, Habe K, Hakamada A, Isoda K. Cytokeratin expression in trichilemmal carcinoma suggests differentiation towards follicular infundibulum. In Vivo. 2006 Sep-Oct. 20(5):583-5. [View Abstract]
  28. Tardío JC. CD34-reactive tumors of the skin. An updated review of an ever-growing list of lesions. J Cutan Pathol. 2009 Jan. 36(1):89-102. [View Abstract]
  29. Hunt SJ, Kilzer B, Santa Cruz DJ. Desmoplastic trichilemmoma: histologic variant resembling invasive carcinoma. J Cutan Pathol. 1990 Feb. 17(1):45-52. [View Abstract]
  30. Illueca C, Monteagudo C, Revert A, Llombart-Bosch A. Diagnostic value of CD34 immunostaining in desmoplastic trichilemmoma. J Cutan Pathol. 1998 Sep. 25(8):435-9. [View Abstract]
  31. Schweiger E, Spann CT, Weinberg JM, Ross B. A case of desmoplastic trichilemmoma of the lip treated with Mohs surgery. Dermatol Surg. 2004 Jul. 30(7):1062-4. [View Abstract]

A patient with trichilemmoma papules on the face.

Clinical image of the face of a patient with Cowden syndrome.

Clinical image of the oral mucosa of a patient with Cowden syndrome.

Clinical image of palmar keratoses in a patient with Cowden syndrome.

Clinical image of sclerotic fibroma in a patient with Cowden syndrome.

Clinical image of multiple trichilemmomas in a patient with Cowden syndrome.

Low-power histologic view of a trichilemmoma.

Mid-power histologic view of a trichilemmoma.

Tumor of the follicular infundibulum.

Low-power histologic view of a desmoplastic trichilemmoma.

High-power histologic view of a desmoplastic trichilemmoma.

A patient with trichilemmoma papules on the face.

Low-power histologic view of a trichilemmoma.

Mid-power histologic view of a trichilemmoma.

Low-power histologic view of a desmoplastic trichilemmoma.

High-power histologic view of a desmoplastic trichilemmoma.

Tumor of the follicular infundibulum.

Clinical image of the face of a patient with Cowden syndrome.

Clinical image of the oral mucosa of a patient with Cowden syndrome.

Clinical image of palmar keratoses in a patient with Cowden syndrome.

Clinical image of sclerotic fibroma in a patient with Cowden syndrome.

Clinical image of multiple trichilemmomas in a patient with Cowden syndrome.